HHT for Clinicians at the 17th National Patient and Family Conference
CME Evaluation Form - Attendees who registered to receive continuing education credit need to print, complete and email the CME evaluation form to [email protected] by August 27, 2014. A certificate will be issued upon receipt of this documentation.
July 18-20, 2014
Santa Clara, California
Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu Syndrome, is a potentially life-threatening genetic disorder that, if properly diagnosed and treated, can be managed and tragedies can be averted. This program is designed for medical professionals who are likely to encounter HHT patients, among them: internal medicine, otolaryngology, gastroenterology, cardiology, interventional radiology, neurology, genetic counseling and nursing.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning and HHT Foundation. The Academy for Continued Healthcare Learning is accredited by the ACCME to provide continuing medical education for physicians.
ACHL has been accredited as an Authorized Provider by the International Association for Continuing Education and Training (IACET). ACHL is authorized by IACET to offer 1.3 CEUs for this program.
Provider approved by the California Board of Registered Nursing, Provider Number 14803 for 12.4 contact hours.
Credit Designation Statement
ACHL designates this educational activity for a maximum of 15.5AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Upon conclusion of this conference, participants will be able to:
- Define the diagnostic criteria for HHT
- Identify treatment options for Pulmonary and Cerebral AVM
- Identify treatment options for Epistaxis
- Identify treatment options for Gastrointestinal and Liver AVM
- Discuss new potential therapies for the management of refractory HHT complications